Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Nicotine Transdermal Patch To Reach Shelves Around Late Spring

This article was originally published in The Tan Sheet

Executive Summary

Perrigo plans to launch its nicotine transdermal patch in late spring or early summer following FDA's Dec. 23 approval of Elan's supplemental NDA to switch the smoking cessation treatment from Rx to OTC status.

You may also be interested in...



TCPI Plans Strategic Alliance For Private Label Nicotine Patch

Technical Chemicals & Products, Inc. plans to develop a "strategic alliance" for its private label nicotine patch. The firm's development of an ANDA for a nicotine patch equivalent to SmithKline Beecham's NicoDerm CQ system is under way, although it has not yet filed an ANDA. Waxman/Hatch marketing exclusivity for SB's nicotine patch expires Aug. 2.

TCPI Plans Strategic Alliance For Private Label Nicotine Patch

Technical Chemicals & Products, Inc. plans to develop a "strategic alliance" for its private label nicotine patch. The firm's development of an ANDA for a nicotine patch equivalent to SmithKline Beecham's NicoDerm CQ system is under way, although it has not yet filed an ANDA. Waxman/Hatch marketing exclusivity for SB's nicotine patch expires Aug. 2.

TCPI Plans Strategic Alliance For Private Label Nicotine Patch

Technical Chemicals & Products, Inc. plans to develop a "strategic alliance" for its private label nicotine patch. The firm's development of an ANDA for a nicotine patch equivalent to SmithKline Beecham's NicoDerm CQ system is under way, although it has not yet filed an ANDA. Waxman/Hatch marketing exclusivity for SB's nicotine patch expires Aug. 2.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel